Business Wire

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™

7.6.2023 17:00:00 EEST | Business Wire | Press release

Share

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/

CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mouse antibodies, researchers relying on CST antibody products have the tools they need to enable fully automated hyperplex imaging at scale.

"As a scientist-led company, we understand the importance of validating antibodies in each application independently. We do not infer performance in IHC based on western blot, for example," said Katie Crosby, Sr. Director, Antibody Applications & Validation at CST. "That's why our team at CST has rigorously tested every one of our IHC-validated antibodies to ensure their specificity and sensitivity in IHC assays."

The COMET™ platform is the first universal, end-to-end spatial biology solution that can assess the location and abundance of a high number of proteins on a single tissue section without the need to conjugate primary antibodies. From early discovery to late-stage translational and clinical research projects, COMET™ can interrogate complex cellular mechanisms to identify new biological pathways in disciplines including immuno-oncology, neuroscience, infectious disease research, and more. COMET™'s walk-away automation maximizes reproducibility while full-tissue preservation capabilities enable additional downstream analysis.

"The COMET™ offers unparalleled flexibility in antibody panel design, and when combined with the comprehensive portfolio of primary antibodies from CST, the research community can confidently generate high-resolution hyperplex images in a matter of days," said Déborah Heintze, CMO at Lunaphore. "The CST products tested on COMET™ gave clear results, demonstrating the capability to produce the high-quality images needed to enable the next generation of spatial biology research."

CST produces and validates more than 99% of its primary antibodies in-house, ensuring shipments will arrive on time and without delay, no matter the size of the order or duration of the project.

"The time and commitment we put into validating and manufacturing our antibodies is recognized by the research community–eight of the 12 most-cited antibodies on CiteAb are from CST, and over one-third of CiteAb's Top 100 list are our products," said Roby Polakiewicz, Chief Scientific Officer at CST. "This partnership provides scientists with that same high level of confidence in antibody sensitivity, specificity, and availability when using Lunaphore's leading spatial biology platform."

Lunaphore and CST will present data about the antibody validation project at the European Association for Cancer Research (EACR) 2023 Congress to be held 12-15 June 2023 in Torino, Italy. Visit the poster at the upcoming show to learn more:

Studying the immune status of the tumor microenvironment with automated hyperplex immunofluorescence

Poster #: EACR23-0431
Date and time: Wednesday, June 14, 10:15 am - 6:15 pm CEST
Speakers:

  • Dr. Pamela Pulimeno, Scientific Marketing Manager, Lunaphore
  • Andrew Thompson, Distributor Manager, EMEA, CST

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CST Media and Press:
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: +1-978-880-3334
Email: marketingpr@cellsignal.com

Lunaphore Media and Press:
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 18:00:00 EET | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making quantum computers a schedulable resource in Slurm by integrating IQM quantum computers. NVIDIA, which has committed to keeping Slurm open source and vendor neutral, announced that Slurm 26.11 adds plugin support for Hierarchical Resources (HRES), allowing a supercomputing center to describe a QPU as a shared, cluster-level resource and connect it to external services, such as the software that manages the device. Until now, quantum computers have not fit the scheduling models Slurm uses for CPUs and GPUs, so integrations have often been built separately f

The Rock-It Company Opens New Regional Office in Nashville16.11.2026 18:00:00 EET | Press release

The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that foundation," said Daniel Rosenthal, President and CEO of The Rock-It Company. "Our longstanding partnership with the Rock organization, combined with the expertise and relationships our teams ha

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 16:45:00 EET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 16:39:00 EET | Press release

Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real capacity. Factbird is a System of Action, built for manufacturers who have plenty of data and struggle to act on it. It connects production data from every line, machine, and operator

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 16:17:00 EET | Press release

Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candidates designed to target the underlying biology of canine aging and help dogs live longer, healthier lives alongside the people who love them. LOY-003 i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye